Aims
To derive and validate a readily useable risk score to identify patients at high-risk of in-hospital ST-segment elevation myocardial infarction (STEMI)-related cardiogenic shock (CS).
Methods and results
In all, 6838 patients without CS on admission and treated by primary percutaneous coronary intervention (pPCI), included in the Observatoire Régional Breton sur l'Infarctus (ORBI), served as a derivation cohort, and 2208 patients included in the obseRvatoire des Infarctus de Cô te-d'Or (RICO) constituted the external validation cohort.
Stepwise multivariable logistic regression was used to build the score. Eleven variables were independently associated with the development of in-hospital CS: age >70 years, prior stroke/transient ischaemic attack, cardiac arrest upon admission, anterior STEMI, first medical contact-to-pPCI delay >90 min, Killip class, heart rate >90/min, a combination of systolic blood pressure <125 mmHg and pulse pressure <45 mmHg, glycaemia >10 mmol/L, culprit lesion of the left main coronary artery, and post-pPCI thrombolysis in myocardial infarction flow grade <3. The score derived from these variables allowed the classification of patients into four risk categories: low (0-7), lowto-intermediate (8) (9) (10) , intermediate-to-high (11) (12) , and high (> _13). Observed in-hospital CS rates were 1.3%, 6 .6%, 11 .7%, and 31.8%, across the four risk categories, respectively. Validation in the RICO cohort demonstrated
Introduction
Despite improvements in the acute management of ST-segment elevation myocardial infarction (STEMI), particularly the widespread use of timely primary percutaneous coronary intervention (pPCI), cardiogenic shock (CS) in this setting still portends a dismal prognosis with 30-day mortality rates approximating 40-45%. [1] [2] [3] [4] While its incidence declined in parallel with the advent of pPCI, CS continues to complicate 2.5% of acute coronary syndromes 3, 5 and 5-15% of STEMI, 1, 2, 4, 6 thus translating into 40-50 000 annual cases in the USA and 60-70 000 patients/year in Europe. 1, 7 Clinical trials testing the use of additional therapies on top of early revascularization of the culprit lesion [immediate multivessel PCI, intra-aortic balloon pump (IABP) or Impella], in the setting of ischaemic CS, failed to demonstrate meaningful reductions in short-to midterm mortality. [8] [9] [10] [11] These results suggest that once the deleterious physiopathological spiral of CS has begun, 12 little prognostic improvement is expected despite invasive medical interventions. Furthermore, mechanical and pharmacological strategies aimed at improving STEMI outcomes, recently evaluated in randomized trials, also failed to reduce infarct size, the incidence of CS, and ultimately short-or mid-term mortality in all-comers populations of anterior STEMI patients. 13, 14 Overall, these data suggest that adjunctive therapies may only be beneficial in patients at high-risk for CS, for whom no reliable risk score currently exists.
From large multicentre registries, we aimed to develop a risk score predicting the in-hospital occurrence of CS amongst STEMI patients treated with pPCI without CS on admission, which in turn could help to better identify patients with impending CS who likely stand to benefit the most from the early initiation of adjunctive therapeutic strategies.
Methods

Data collection
Data from the previously described Observatoire Régional Breton sur l'Infarctus (ORBI) 15 were used as a derivation cohort. 
Patients
Patients enrolled in ORBI between June 2006 and December 2015 without CS on admission and treated with pPCI, were included in this analysis ( Figure 1 ) to develop the risk-scoring system. Using the same inclusion criteria, patients enrolled in RICO between January 2002 and June 2016, with complete data regarding risk factors identified in the derivation cohort, were included in the validation cohort.
Definitions
ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction. 17 Because classic haemody- 
Statistical analysis
Data are summarized as number (percentages) for categorical variables. Continuous variables are expressed as median (interquartile range). Qualitative data were compared using the v 2 or Fisher exact tests while quantitative data were compared using the Mann-Whitney U test. All tests were 2-sided at the 0.05 significance level. The derivation cohort was used to identify predictors of in-hospital occurrence of CS and to develop a risk-scoring system which was tested in the validation cohort. Univariable logistic regression with the development of in-hospital CS as the dependent variable was performed on complete cases. Receiver-operator curves were used to categorize continuous variables with a P-value <0.05 in univariable analysis by selecting clinically relevant cut-offs, which were the closest to the optimal cutoff according to the Youden's index. Overall, 1.03% of data were missing and a total of 26.3% of patients had at least 1 missing value. For the purposes of multivariable analysis, assuming missing data were randomly missing, multiple imputation using Monte Carlo Markov chained Variables with a P-value <0.05 in univariable analysis were entered in a multivariable logistic regression model to derive adjusted odds ratio (OR) with 95% confidence intervals (95% CI) which were then combined using Rubin's rule. 19 A stepwise process was applied to identify the best parsimonious set of predictors. To allow the creation of a readily useable risk score in routine practice, creatinine level on admission, which may not be available at the end of a pPCI procedure, was not included in the model. Moreover, procedural variables depending on the operator's choice and likely influenced by patient's presentation such as access site and type of stent used were not included in the model. Multicollinearity between the variables in the final model was assessed by calculation of the variance inflation factor and the tolerance. A 1000-fold bootstrap resampling was performed to calculate a shrinkage factor which was applied as a multiplier to regression coefficients of the final model to avoid overfitting to the development data. 20 These corrected coefficients of significant multivariable predictors (P < 0.05) were then divided by the lowest coefficient value in the model and rounded to the nearest integer to assign a risk score weight to each predictor in the model. Each patient's risk score was calculated by adding these weights. An objective assessment of calibration was obtained by performing the Hosmer-Lemeshow goodness-of-fit test and by plotting observed vs. predicted incidence rate across deciles of risk score. In both cohorts, the predictive performance of the risk score was assessed by the c-statistic which was 1000-fold cross-validated in the development cohort to evaluate the expected decrease in discriminative ability among new patients. 20 Clinical usefulness was evaluated using decision curve analysis, 20 by estimating the net benefit of using the model to risk-stratify patients according to different decision thresholds of in-hospital CS risk, compared with the two alternatives of assuming that none or all will be at high risk, as well as a model based only on admission haemodynamic variables (Killip class, heart rate, and the combination of systolic blood pressure and pulse pressure) and a model based on the admission shock index (heart rate/systolic blood pressure), a known predictor of short-term outcomes in STEMI patients. 21 Table 1 provides a comparison of baseline and procedural characteristics of patients as well as in-hospital outcomes within the derivation and validation cohorts. Patients in the validation cohort were older, more often female and harboured a higher rate of most baseline comorbidities. Presentation as cardiac arrest (4.8 vs. 2.1%, P < 0.001) and admission to a non-pPCI-capable centre (31.6 vs. 15 .8%, P < 0.001) were more common in the validation cohort, which translated in a longer median first medical contact-to-pPCI delay (144 vs. 95 min, P < 0.001). Although patients from the RICO registry were more likely to harbour multivessel coronary disease (51.5 vs. 47.2%, P = 0.001), complete revascularization was equally achieved in both groups after the index procedure. Cardiogenic shock occurred in 8.3% of patients in the validation cohort compared with 4.3% of patients in the derivation cohort (P < 0.001). In keeping with their higher baseline risk profile, RICO patients had a lower in-hospital survival than ORBI patients (94.6 vs. 96 .7%, P < 0.001) and displayed higher rates of most STEMI complications. In-hospital mortality rates of CS patients were 43.7% and 35.5% in the derivation and validation cohort, respectively. 
Predictors of in-hospital cardiogenic shock
Univariable predictors of in-hospital development of CS in the derivation cohort are summarized in Table 2 .
Eleven predictors, reported in Figure 2 , were independently associated with in-hospital occurrence of CS by multivariable analysis 
ORBI risk score building
Points assigned to each variable of the risk-scoring system were derived from the regression coefficients of the final multivariable model (Figure 2) . The score was calculated by adding each component and theoretically ranged from 0 to 36. An online calculator is available at www.orbiriskscore.com. In the derivation cohort, the score ranged from 0 to 24. The relationship between the score value and the predicted incidence of in-hospital CS is shown in Figure 3 . The OR associated with a one point increase of the score was 1.36 (95% CI 1.32-1.40; P < 0.001). The c-statistic of the score was 0.84 (95% CI 0.81-0.87) in the derivation cohort. Cross-validation Figure 4 provides the calibration plot of predicted vs. observed incidence of in-hospital CS in the derivation cohort across deciles of risk score confirming an excellent calibration. Levels of risk were defined according to the predicted incidence of in-hospital CS: low-risk for a score < _7 corresponding to a predicted incidence <4% (4446 patients, 77.4% of the development cohort), low-to-intermediate risk for a score of 8-10 corresponding to a predicted incidence > _4% and <10% (777 patients; 13.5%), intermediate-to-high risk for a score of 11 or 12 corresponding to a predicted incidence > _10% and <15% (247 patients, 4.3%), and high risk for a score > _13 corresponding to a predicted incidence > _15% (274 patients, 4.8%). Observed incidences of in-hospital CS according to these cut-offs were 1.3%, 6.6%, 11.7%, and 31.8%, respectively, in the derivation cohort ( Figure 5 ).
Score validation
In the validation cohort, the c-statistic of the final model was 0.80 (95% CI 0.77-0.84) with a P-value of the Hosmer-Lemeshow test of 0.61. The score showed only weakly reduced discrimination in the validation cohort (c-statistic 0.80, 95% CI 0.77-0.83) with a P-value of the Hosmer-Lemeshow test of 0.69. Predicted and observed CS incidences across deciles of risk score for the validation cohort are depicted in Figure 4 . The distribution of patients of the validation cohort according to their predicted risk was as follows: 68.3% (n = 1509) low-risk, 15 .0% (n = 330) low-to-intermediate risk, 7 .0% (n = 155) intermediate-to-high risk, and 9.7% (n = 214) high-risk. Observed incidence of in-hospital CS according to these increasing levels of risk was 3.1%, 10.6%, 18.1%, and 34.1%, respectively, in the validation cohort ( Figure 5) . The distributions of patients according to risk score and the occurrence of in-hospital CS in the derivation and validation cohorts are shown in Supplementary material online, Figure S1 . The prediction model was further evaluated by incorporating clinical consequences throughout the probability ranges, by the use of a decision curve analysis ( Figure 6) . The results demonstrated that for relevant decision thresholds, the ORBI risk score model provided a substantial net clinical benefit compared with a model including only admission haemodynamic variables (Killip Class II or III, heart rate-> 90/min, combination of systolic blood pressure < 125 mmHg, and pulse pressure < 45 mmHg) and a model using the admission shock index. For a decision threshold of 5% of in-hospital CS risk, compared with these models, the ORBI risk score would identify 10 additional cases, without identifying any additional false positive, in a population of 1000 patients with a 4.3% incidence of in-hospital CS.
Discussion
The present study is, to the best of our knowledge, the first to provide a readily useable scoring system to identify STEMI patients with 
impending CS following pPCI. In this large homogeneous cohort of pPCI-treated STEMI patients without CS on admission, 11 routinely collected variables, 8 patient-related, and 3 procedure-related, available in the catheterization laboratory, independently predicted the development of in-hospital CS post-pPCI. The ORBI risk score (Take home figure), including these variables, showed good predictive ability and calibration across the significantly different populations of the derivation and validation cohorts, further supporting the quality of the external validation. Being based on simple categorical parameters, the score can be easily calculated in routine clinical practice. This score could be useful in the selection of high-risk patients, especially in the setting of future randomized trials designed to provide a tailored aggressive management to the so-called 'pre-shock' patients.
Although, in the setting of STEMI, acute heart failure remains one of the strongest predictors of short-term mortality in the contemporary era, regardless of its timing or severity, this relationship is mainly driven by patients experiencing CS. 2 In a recent series of 6282 pPCI-treated patients, we demonstrated an overall rate of approximately 8% of STEMI-related CS with 54% of cases occurring after hospital admission. 2 Interestingly, in a decade-long evaluation of STEMI patients included at 11 centres in Massachusetts between 2001 and 2011, Goldberg et al. 22 demonstrated a relatively unchanged 4% incidence of in-hospital development of CS.
Notwithstanding the decline of case-fatality rate observed over the past decades, it is fair to say that the 40% short-term mortality rate still observed in recent series 6, 9 remains unacceptably high and testifies to the unresolved clinical challenge posed by CS. In keeping with this point, it should be highlighted that the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial, which spurred the widespread use of early reperfusion, (i.e. the last successful innovation in ischaemic CS management), was published more than 15 years ago. 18 Since then, the systematic use of IABP, compared with early revascularization alone, failed to improve systemic inflammation, tissue oxygenation, and survival in ischaemic CS patients. 9 Moreover, there is currently no evidence that more elaborative left ventricular assist devices such as the Impella (PL2.5 or CP, Abiomed, Danvers, MA, USA) or the TandemHeart TM (CardiacAssist Inc., Pittsburgh, PA, USA), provide clinical benefits above and beyond an IABP, other than providing greater haemodynamic support. 11, 23 Recently, Thiele et al. 8 randomized 706 patients with acute myocardial infarction-related CS to immediate multivessel or culprit lesion-only pPCI. Patients in the immediate multivessel pPCI group exhibited a higher rate of the 30-day primary composite endpoint of all-cause death and renal replacement therapy, including a significant increase in 30-day mortality. The CULPRIT-SHOCK trial, adding to the long list of negative trials in the CS setting, will therefore likely have a major clinical impact as it contradicts latest European Guidelines which gave nonculprit lesion pPCI during the index procedure a IIaC recommendation. 24 A pharmacological strategy aimed to target circulatory failure, Figure 3 Relationship between the score value and the predicted incidence of in-hospital cardiogenic shock. CS, cardiogenic shock. 25 Collectively, these data suggest that strategies tackling a single aspect of the complex, deleterious, physiopathological spiral underlying CS may be 'too little, too late' to achieve a sustained reversal of this vicious circle, especially when multiorgan dysfunction syndrome has developed. 12, 23 In clinical practice, CS encompasses a spectrum ranging from 'preshock' to overt severe refractory shock. 26 Identifying the former state is extremely appealing as it may reduce short-term mortality by preventing progression to overt CS by promptly initiating aggressive management strategies. Nevertheless, albeit widely used, this term has no generally accepted definition and the current literature is elusive regarding factors that may help delineate this high-risk entity. 26 Recent analyses identified older age, diabetes mellitus, stroke, treatment delays, anterior STEMI, heart rate, systolic blood pressure, cardiac arrest, elevated glycaemia, and impaired renal function to associate with the development of in-hospital CS. 22, 27 Moreover, as in the present model, age, prior stroke, admission glycaemia >10.6 mmol/L, and post-pPCI thrombolysis in myocardial infarction (TIMI) flow grade <3 were also included in the recently published IABP-SHOCK II risk score. 28 This score was designed to predict 30-day mortality in acute myocardial infarction-related CS patients, demonstrating good predictive ability (with c-statistic of 0.79 and 0.73 in its derivation and validation cohorts, respectively). In addition to the Figure 5 Observed incidence of cardiogenic shock. Observed incidence of cardiogenic shock according to categories of the Brittany Regional
Infarction Observatory risk score in the derivation and validation cohorts. above-mentioned parameters, it also includes admission levels of creatinine >1.5 mg/dL and blood lactate > 5 mmol/L. The former parameter was knowingly excluded from our multivariable model as it may not be available following the pPCI procedure yet still demonstrated univariable association with shock development in the present study. Blood lactate was not routinely recorded in our cohorts and therefore could not be tested as a potential predictor of CS, explaining the difference between the IABP and ORBI risk scores. Finally, in a large German registry including 1333 ischaemic CS patients, 29 older age, culprit lesion of the left main, post-pPCI TIMI flow <3 and longer delays between symptoms, and pPCI were also predictors of inhospital mortality which reinforces the prognostic impact of factors identified in the present analysis. The ORBI risk score presented in this study has several strengths. First, it has been developed from a large homogeneous population of STEMI patients treated by pPCI, which essentially represents contemporary practices. Second, it includes dichotomized variables that are easily collected and available in the catheterization laboratory, and it can be quickly calculated in routine practice as it does not require complex processing of the variables. Third, as previously discussed, it efficiently addresses a major unmet clinical need, refining the identification of patients at high-risk of CS development at the end of a pPCI procedure which may be the most suitable time to initiate early adjunctive therapies. Fourth, it has been validated in an external cohort exhibiting significant differences in the baseline characteristics of included patients compared with the derivation cohort, further supporting the validity and reliability of this risk score over a large span of baseline in-hospital CS risk. And fifth, it has demonstrated superior clinical benefit compared with models based on haemodynamic variables or the shock index which approximate the intuitive bedside assessment performed by clinicians upon admission of these STEMI patients.
A single risk score is unlikely to include all relevant parameters allowing risk estimation and as such will not substitute for a thorough clinical evaluation. However, the ORBI risk score provides a simple tool to help decision making, which may have several clinical implications. The higher risk patients may benefit from an early transfer to an intensive cardiac care unit with experience in the management of CS, especially in mechanical circulatory support. Moreover, avoidance of the use of b-blockers and angiotensin-converting enzyme inhibitors in the very early management of high-risk patients may prevent iatrogenic shock. In recent years, complete revascularization demonstrated improved clinical outcomes over culprit lesion-only revascularization in haemodynamically stable STEMI patients. 30 However, the optimal timing of complete revascularization remains unknown. Conceivably, by alleviating the ischaemic burden of noninfarct territories, immediate complete revascularization may prevent the occurrence of overt CS among high-risk patients. However, as previously stated, this strategy resulted in worse short-term outcomes, including 30-day mortality, compared with culprit lesion-only pPCI when CS-driven systemic physiopathological alterations already started. 8 Based on recent randomized trials in haemodynamically stable patients, a strategy of routine PCI of non-infarct-related arteries lesions before hospital discharge (thus including during the index procedure) has recently been given a Class IIaA recommendations in the latest European guidelines. 24 Although the systematic use of IABP has yet to show proven benefit in an all-comers STEMI population, evidence from a small CRISP-AMI sub-study suggest it might have positive effect in selected high-risk patients with persistent ischaemia. 31 Therefore, the use of devices with low rates of complications such as IABP to allow the severely ischaemic myocardium to recover may be evaluated in high-risk patients as identified by the ORBI risk score. Finally, pharmacological strategies targeting the systemic inflammatory response syndrome promoting overt CS 1,12,25 may also be guided by the present risk score. 
Study limitations
The diagnosis of CS was not adjudicated but made locally by the treating physician mainly by clinical judgement without pre-specified strict haemodynamic or echocardiographic criteria. However, the incidences and case-fatality rates of in-hospital CS reported in our derivation and validation cohorts are consistent with the current literature and make under-or over-reporting of CS unlikely. Moreover, despite this somewhat 'subjective' reporting of CS, the score performed well in both cohorts highlighting its predictive ability. Certain biological parameters of prognostic value in the STEMI setting, such as white blood cell count or serum lactate levels, were not available for testing in our database. Furthermore, the TIMI flow grade was not assessed by a central core laboratory which may lead to discrepancies between operators and overestimation of this reperfusion indicator. 32 Thus, the true predictive impact of an 'adequately' assessed TIMI flow grade might differ from the odds identified in the present study. However, the ORBI risk score was designed from routine practice for routine practice. Therefore, the investigator-reported TIMI flow grade used in this study, more accurately depicting real life, is rather an asset in this setting. Given the good predictive performances of the score in our two large cohorts of STEMI patients with multiple operators, it also supports the reliability of the risk-scoring system. Finally, it should be highlighted that more sophisticated prediction models such as those involving machine learning, 33 may have provided improved model performance however regression methods have the advantage of allowing an easy conversion of the model coefficients into a point-based score for routine practice use.
Conclusion
The ORBI risk score is a simple and efficient tool that may be calculated at the end of a pPCI procedure in routine practice to identify patients with a high-risk of in-hospital development of CS. It might provide valuable assistance to risk-stratify patients and facilitate clinical decision making as well as patients' selection for future prospective randomized trials.
Take home figure The Brittany Regional Infarction Observatory risk score model. The Brittany Regional Infarction Observatory risk score was created using stepwise multivariable regression to predict the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Score weights were determined by rounding the respective parameters adjusted odds ratio. The score, theoretically ranging from 0 to 36 points, was divided in risk category according to the predicted incidence of cardiogenic shock: low: 0 to 7 points; low-to 
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